Tolerx, Inc., After a Decade and $150 Million, Eagerly Awaits Data from Big Diabetes Trial
Xconomy.com -- By the end of this year, the people at Tolerx will have a good sense of what they’ve created with $150 million of investment over the past decade. If the Cambridge, MA-based company has played its cards right, it should have positive results from a pivotal clinical trial of a drug with an unorthodox approach for fighting Type 1 diabetes.